1. bookVolumen 65 (2015): Edición 4 (December 2015)
Detalles de la revista
License
Formato
Revista
eISSN
1846-9558
Primera edición
28 Feb 2007
Calendario de la edición
4 veces al año
Idiomas
Inglés
Acceso abierto

Deciphering nifedipine in vivo delivery from modified release dosage forms: Identification of food effect

Publicado en línea: 17 Dec 2015
Volumen & Edición: Volumen 65 (2015) - Edición 4 (December 2015)
Páginas: 427 - 441
Aceptado: 02 Sep 2015
Detalles de la revista
License
Formato
Revista
eISSN
1846-9558
Primera edición
28 Feb 2007
Calendario de la edición
4 veces al año
Idiomas
Inglés

1. D. Fleisher, C. Li, Y. Zhou, L. H. Pao and A. Karim, Drug, meal and formulation interactions influencing drug absorption after oral administration clinical implications, Clin. Pharmacokinet. 36 (1999) 233-254; DOI: 10.2165/00003088-199936030-00004.10.2165/00003088-199936030-00004Search in Google Scholar

2. K. A. Lentz, Current methods for predicting human food effect, The AAPS Journal 10 (2008) 282-288; DOI: 10.1208/s12248-008-9025-8.10.1208/s12248-008-9025-8Search in Google Scholar

3. FDA/CDER (2002), Guidance for Industry: Food-effect Bioavailability and Fed Bioequivalence Studies.Search in Google Scholar

4. EMA/CPMP (2010), Guideline on the Investigation of Bioequivalence, CPMP/EWP/QWP/1401/98 Rev. 1/ Corr **.Search in Google Scholar

5. EMA/CHMP (2014), Guideline on the Pharmacokinetic and Clinical Evaluation of Modified Release Dosage Forms, EMA/CPMP/EWP/280/96 Corr1.Search in Google Scholar

6. W. Jiang, S. Kim, X. Zhang, R. A. Lionberger, B. M. Davit, D. P. Conner and L. X. Yu, The role of predictive biopharmaceutical modeling and simulation in drug development and regulatory evaluation, Int. J. Pharm. 418 (2011) 151-160; DOI: 10.1016/j.ijpharm.2011.07.024.10.1016/j.ijpharm.2011.07.024Search in Google Scholar

7. E. S. Kostewicz, L. Aarons, M. Bergstrand, M. B. Bolger, A. Galetin, O. Hatley, M. Jamei, R. Lloyd, X. Pepin, A. Rostami-Hodjegan, E. Sjögren, C. Tannergren, D. B. Turner, C. Wagner, W. Weitschies and J. Dressman, PBPK models for the prediction of in vivo performance of oral dosage forms, Eur. J. Pharm. Sci. 57 (2014) 300-321; DOI: 10.1016/j.ejps.2013.09.008.10.1016/j.ejps.2013.09.008Search in Google Scholar

8. E. S. Kostewicz, B. Abrahamsson, M. Brewster, J. Brouwers, J. Butler, S. Carlert, P. A. Dickinson, J. Dressman, R. Holm, S. Klein, J. Mann, M. McAllister, M. Minekus, U. Muenster, A. Müllertz, M. Verwei, M. Vertzoni, W. Weitschies and P. Augustijns, In vitro models for the prediction of in vivo performance of oral dosage forms, Eur. J. Pharm. Sci. 57 (2014) 342-366; DOI: 10.1016/j. ejps.2013.08.024.Search in Google Scholar

9. EMA, QWP (2012), Guideline on Quality of Oral Modified Release Products, Draft, EMA/ 492713/2012.Search in Google Scholar

10. B. Abrahamsson, K. Roos and J. Sjogren, Investigation of prandial effects on hydrophilic matrix tablets, Drug Dev. Ind. Pharm. 25 (1999) 765-771; DOI: 10.1081/DDC-100102236.10.1081/DDC-100102236Search in Google Scholar

11. J. Parojčić, D. Vasiljević, S. Ibrić and Z. Đurić, Tablet disintegration and drug dissolution in viscous media: Paracetamol IR tablets, Int. J. Pharm. 355 (2008) 93-99; DOI: 10.1016/j.ijpharm.2007.11.058.10.1016/j.ijpharm.2007.11.058Search in Google Scholar

12. B. Abrahamsson, M. Alpsten, B. Bake, U. E. Jonsson, M. Eriksson-Lepkowska and A. Larsson, Drug absorption from nifedipine hydrophilic matrix extended-release (ER) tablet - comparison with an osmotic pump tablet and effect of food, J. Control. Rel. 52 (1998) 301-310; DOI: 10.1016/ S0168-3659(97)00267-8.10.1016/S0168-3659(97)00267-8Search in Google Scholar

13. C. Wagner, K. Thelen, S. Willmann, A. Selen and J. B. Dressman, Utilizing in vitro and PBPK tools to link ADME characteristics to plasma profiles: Case example nifedipine immediate release formulation, J. Pharm. Sci. 102 (2013) 3205-3219; DOI: 10.1002/jps.23611.10.1002/jps.23611Search in Google Scholar

14. B. S. Schug, E. Brendel, D. Wolf, M. Wonnemann, M. Wargenau and H. H. Blume, Formulationdependent food effects demonstrated for nifedipine modified-release preparations marketed in the European Union, Eur. J. Pharm. Sci. 15 (2002) 279-285; DOI: 10.1016/S0928-0987(02)00008-8.10.1016/S0928-0987(02)00008-8Search in Google Scholar

15. M. Wonnemann, B. Schug, K. Schmücker, E. Brendel, P. A. van Zwieten and H. Blume, Significant food interactions observed with a nifedipine modified-release formulation marketed in the European Union, Int. J. Clin. Pharmacol. Ther. 44 (2006) 38-48; DOI: 10.5414/CPP44038.10.5414/CPP44038Search in Google Scholar

16. M. Wonnemann, B. S. Schug, M. Anschutz, E. Brendel, G. De Nucci and H. H. Blume, Comparison of two marketed nifedipine modified-release formulations: An exploratory clinical food interaction study, Clin. Ther. 30 (2008) 48-58; DOI: 10.1016/j.clinthera.2008.01.001.10.1016/j.clinthera.2008.01.001Search in Google Scholar

17. N. Patel, S. Polak, M. Jamei, A. Rostami Hodjegan and D. B. Turner, Quantitative prediction of formulation-specific food effects and their population variability from in vitro data with the phys iologically-based ADAM model: A case study using the BCS/BDDCS Class II drug nifedipine, Eur. J. Pharm. Sci. 57 (2014) 240-249; DOI: 10.1016/j.ejps.2013.09.006.10.1016/j.ejps.2013.09.006Search in Google Scholar

18. T. J. Rashid, U. Martin, H. Clarke, D. G. Waller, A. G. Renwick and C. F. George, Factors affecting the absolute bioavailability of nifedipine, Br. J. Clin. Pharmacol. 40 (1995) 51-58; DOI: 10.1111/ j.1365-2125.1995.tb04534.x.10.1111/j.1365-2125.1995.tb04534.xSearch in Google Scholar

19. J. C. Loo and S. Riegelman, New method for calculating the intrinsic absorption rate of drugs, J. Pharm. Sci. 57 (1968) 918-928; DOI: 10.1002/jps.2600570602.10.1002/jps.2600570602Search in Google Scholar

20. B. Agoram, W. S. Woltosz and M. B. Bolger, Predicting the impact of physiological and biochemical processes on oral drug bioavailability, Adv. Drug Deliv. Rev. 50 (2001) S41-S67; DOI: 10.1016/ S0169-409X(01)00179-X.10.1016/S0169-409X(01)00179-XSearch in Google Scholar

21. M. Ilić, J. Đuriš, I. Kovačević, S. Ibrić and J. Parojčić, In vitro - in silico - in vivo drug absorption model development based on mechanistic gastrointestinal simulation and artificial neural networks: Nifedipine osmotic release tablets case study, Eur. J. Pharm. Sci. 62 (2014) 212-218; DOI: 10.1016/j.ejps.2014.05.030.10.1016/j.ejps.2014.05.03024911992Search in Google Scholar

22. E. Jantratid, N. Janssen, C. Reppas and J. B. Dressman, Dissolution media simulating conditions in the proximal human gastrointestinal tract: an update, Pharm. Res. 25 (2008) 1663-1676; DOI: 10.1007/s11095-008-9569-4.10.1007/s11095-008-9569-418404251Search in Google Scholar

23. Summary of Product Characteristics: Adalat modified release tablets, Bayer plc, revision date April 12, 2012 (www.medicines.org.uk).Search in Google Scholar

24. K. Hirasawa, W. F. Shen, D. T. Kelly, G. Roubin, K. Tateda and J. Shibata, Effect of food ingestion on nifedipine absorption and haemodynamic response, Eur. J. Clin. Pharmacol. 28 (1985) 105-107; DOI: 10.1007/BF00635716.10.1007/BF006357163987781Search in Google Scholar

25. V. Challenor, D. G. Waller, B. S. Gruchy, A. G. Renwick, C. F. George, E. T. McMurdo and J. McEwen, The effect of food and posture on the pharmacokinetics of a biphasic release preparation of nifedipine, Br. J. Clin. Pharmacol. 22 (1986) 565-570; DOI: 10.1111/j.1365-2125.1986.tb02936.x.10.1111/j.1365-2125.1986.tb02936.x14011743790403Search in Google Scholar

26. J. Armstrong, V. F. Challenor, B. S. Macklin, A. G. Renwick and D. G. Waller, The influence of two types of meal on the pharmacokinetics of a modified-release formulation of nifedipine (Adalat Retard), Eur. J. Clin. Pharmacol. 53 (1997) 141-143; DOI: 10.1007/s002280050352.10.1007/s0022800503529403286Search in Google Scholar

27. FDA/CDER (1998), Bioequivalence Review: Application Number 75-108.Search in Google Scholar

28. K. B. Nemes, V. Horvath, G. Grezal, G. Horvai, A. Hrabeczy-Pall, E. Kocsi, S. Drabant, M. Csorgo, G. Rencez and I. Klebovich, Food interaction pharmacokinetic study of Cordaflex 20 mg retard film tablet in healthy volunteers, Int. J. Clin. Pharmacol. Ther. 36 (1998) 263-269.Search in Google Scholar

29. B. S. Schug, E. Brendel, M. Wonnemann, D. Wolf, M. Wargenau, A. Dingler and H. H. Blume, Dosage form-related food interaction observed in a marketed once-daily nifedipine formulation after a high-fat American breakfast, Eur. J. Clin. Pharmacol. 58 (2002) 119-125; DOI: 10.1007/s00228-002-0444-7.10.1007/s00228-002-0444-712012144Search in Google Scholar

30. B. S. Schug, E. Brendel, E. Chantraine, D. Wolf, W. Martin, R. Schall and H. H. Blume, The effect of food on the pharmacokinetics of nifedipine in two slow release formulations: pronounced lagtime after a high fat breakfast, Br. J. Clin. Pharmacol. 53 (2002) 582-588; DOI: 10.1046/j.1365-2125. 2002.01599.x.Search in Google Scholar

31. J. M. Custodio, C. Y. Wu and L. Z. Benet, Predicting drug disposition, absorption/elimination/ transporter interplay and the role of food on drug absorption, Adv. Drug Deliv. Rev. 60 (2008) 717-733; DOI: 10.1016/j.addr.2007.08.043.10.1016/j.addr.2007.08.043229281618199522Search in Google Scholar

32. S. Klein, The use of biorelevant dissolution media to forecast the in vivo performance of a drug, The AAPS Journal 12 (2010) 397-406; DOI: 10.1208/s12248-010-9203-3.10.1208/s12248-010-9203-3289543820458565Search in Google Scholar

33. C. Piovella, Clinical efficacy and bioavailability of a sustained release nifedipine formulation, Arzneimittelforschung 37 (1987) 832-835. Search in Google Scholar

Artículos recomendados de Trend MD

Planifique su conferencia remota con Sciendo